MedTrace Logo

Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes

NCT00966043 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2015-10-28

No results posted yet for this study

Summary

CYPTAM-BRUT 3 is a prospective, multicentric study in Belgium within the CYPTAM study of the Leiden University Medical Center (NTR1509) including postmenopausal women receiving tamoxifen for estrogen-receptor positive breast cancer in the adjuvant setting. The primary endpoint is the difference in uterine changes between women with a normal versus low TAS after 3 months of tamoxifen use. Secondary endpoints are serum metabolite concentrations, serum follicle-stimulating hormone level, serum sex hormone-binding globulin level and menopausal symptoms. These patients are registered in the Leiden protocol with time to breast cancer event as primary endpoint.

Conditions

  • Breast Neoplasms

Sponsors & Collaborators

  • Vlaamse Vereniging voor Obstetrie en Gynaecologie

    lead OTHER

Principal Investigators

  • Patrick Neven · UZ Leuven

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966043 on ClinicalTrials.gov